연구성과로 돌아가기
2024 연구성과 (177 / 286)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | Meeting Abstract | Impact of Medication Adherence to Active Tuberculosis Occurrence in Pediatric Population With Latent Tuberculosis Infection: A Population-Based Cohort Study In South Korea | Jeon, SooMin; Kim, Dohyang; Kwon, Jin-Won | Jeju Natl Univ, Jeju, South Korea; Daegu Univ, Gyongsan, South Korea; Kyungpook Natl Univ, Daegu, South Korea | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | PHARMACOEPIDEM DR S | 1053-8569 | 1099-1557 | 33 | SCIE | PHARMACOLOGY & PHARMACY;PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | 2024 | 2.4 | 37.4 | 0 | English | 2024 | 2024-11 | 바로가기 | 바로가기 | |||||||||||||||||
| ○ | Meeting Abstract | Risk of Safety Outcomes Associated With The Long-Term Use of Oral Corticosteroids: A Nested Case-Control Study of 1 Million Patients With Atopic Dermatitis | Jang, Yong Hyun; Choi, Eun-Young; Lee, Hyesung; Woo, Jieun; Park, Sohee; Noh, Yunha; Jeon, Ja-Young; Yoo, Eun-Young; Shin, Ju-Young; Lee, Yang Won | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Dermatol, Daegu, South Korea; Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea; Sungkyunkwan Univ, Dept Biohlth Regulatory Sci, Suwon, South Korea; McGill Univ, Aston Pharm Sch, Montreal, PQ, Canada; McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; Pfizer Pharmaceut Korea Ltd, Seoul, South Korea; Konkuk Univ, Sch Med, Dept Dermatol, Seoul, South Korea | Choi, Eun-Young/JXO-0422-2024 | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | PHARMACOEPIDEM DR S | 1053-8569 | 1099-1557 | 33 | SCIE | PHARMACOLOGY & PHARMACY;PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | 2024 | 2.4 | 37.4 | 0 | English | 2024 | 2024-11 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | Meeting Abstract | Severe Cutaneous Adverse Reactions Associated with Antibiotics in Pediatric Patients | Hwang, Hyeyone; Jeon, SooMin; Ryu, Juhee; Kwon, Jin-Won | Kyungpook Natl Univ, Daegu, South Korea; Jeju Natl Univ, Jeju, South Korea | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | PHARMACOEPIDEM DR S | 1053-8569 | 1099-1557 | 33 | SCIE | PHARMACOLOGY & PHARMACY;PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | 2024 | 2.4 | 37.4 | 0 | English | 2024 | 2024-11 | 바로가기 | 바로가기 | |||||||||||||||||
| ○ | ○ | Article | Analysis of microclimate temperature and relative humidity distribution of local poultry house in a subtropical area of Nigeria | The literature lacks information on the distribution of micro- climate parameters, which is necessary for designing the ventilation system in poultry houses in Nigeria to guarantee optimal microclimate conditions. This study looked into the distribution patterns of relative humidity (RH) and temperature in a typical local poultry house. The specific objectives were to: i) analyze the vertical and horizontal distributions of the microclimate parameters in battery cage poultry housing and deep litter poultry housing; ii) identify whether the distribution is homogenous or heterogeneous; iii) identify the data spread of parameters. For this study, a locally located experimentally intensive naturally ventilated poultry house was used. It was made up of air-walled poultry housing systems for deep litter (DL) and battery cage (BC) birds. The RH distributions and daytime, nighttime, rainy, and dry season temperatures in the BC and DL poultry housing were exam- ined. Day and nighttime temperature differences of about 1.2 degrees C were noted between the poultry house and surrounding air. The poultry housing had a heterogeneous distribution of both temperature and relative humidity. The optimal values were reached by about 5% and 67-73% of the daytime and nighttime temperature data, respectively, and 37-41% of the daytime relative humidity. | Ogunlowo, Qazeem Opeyemi; Azeez, Adedayo Afeez; Na, Wook Ho; Rabiu, Anis; Adesanya, Misbaudeen Aderemi; Zakir, Ezatullah; Ijadunola, John Ademola; Afolabi, Bukola Olanrewaju; Kosemani, Babajide Saheed; Ilori, Titus Adeyinka; Lee, Hyun-Woo | Kyungpook Natl Univ, Coll Agr & Life Sci, Dept Agr Civil Engn, Daegu, South Korea; Fed Coll Agr Ibadan, Dept Agr & Bioenvironm Engn, Ibadan, Nigeria; Kyungpook Natl Univ, Smart Agr Innovat Ctr, Daegu, South Korea; Olabisi Onabanjo Univ, Fac Engn, Dept Agr Engn, Ago Iwoye, Nigeria | OGUNLOWO, QAZEEM/ABB-5386-2021; Adesanya, Misbaudeen/AAA-4664-2022; RABIU, Anis/JXO-1947-2024 | 57265471800; 59198905300; 57211208368; 57264527100; 57264527200; 58068214600; 59198905400; 59198410300; 57209433883; 53863486200; 57209160180 | whlee@knu.ac.kr; | JOURNAL OF AGRICULTURAL ENGINEERING | J AGRIC ENG-ITALY | 1974-7071 | 2239-6268 | 55 | 2 | SCIE | AGRICULTURAL ENGINEERING | 2024 | 2.5 | 37.5 | 0 | 2025-05-07 | 0 | 0 | temperature; relative humidity; distribution; poultry; microclimate; heat stress | SYSTEM | distribution; heat stress; microclimate; poultry; relative humidity; temperature | English | 2024 | 2024 | 10.4081/jae.2024.1561 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | Article | Dynamic neural network modeling of thermal environments of two adjacent single-span greenhouses with different thermal curtain positions | Scientific methods must be used to forecast the greenhouse microclimate, which is influenced by crop management practices and the surrounding macroclimate, in order to produce a marketable yield. Using input parameters like indoor air temperature, relative humidity, solar radiation, indoor roof temperature, and indoor relative humidity, the MATLAB tool NARX was utilized in this study to predict the strawberry yield, indoor air temperature, relative humidity, and vapor pressure deficit. To increase the model's accuracy, the data were normalized. The Levenberg-Marquardt backpropagation algorithm was used to develop the model. A number of evaluation metrics, including the coefficient of determination, mean square error, root mean square error, mean absolute deviation, and Nash-Sutcliffe efficiency coefficient, were used to assess the models' accuracy. The outcomes demonstrated a high degree of accuracy of the models, with no discernible variation between the experimental and predicted values. It was discovered that the vapor pressure deficit model was the most significant since it affects crop metabolic activities and its precision can be utilized as a parameter for indoor climate control. | Akpenpuun, Timothy Denen; Ogunlowo, Qazeem Opeyemi; Na, Wook-Ho; Dutta, Prabhat; Rabiu, Anis; Adesanya, Misbaudeen Aderemi; Nariman, Mohammadreza; Zakir, Ezatullah; Kim, Hyeon Tae; Lee, Hyun-Woo | Univ Ilorin, Dept Agr & Biosyst Engn, Ilorin, Nigeria; Kyungpook Natl Univ, Smart Agr Innovat Ctr, Daegu, South Korea; Kyungpook Natl Univ, Coll Agr & Life Sci, Dept Agr Civil Engn, Daegu 41566, South Korea; Fed Coll Agr, Dept Agr & Bioenvironm Engn, Moor Plantat, Ibadan, Nigeria; Kyungpook Natl Univ, Dept Food Secur & Agr Dev, Daegu, South Korea; Univ Tehran, Coll Agr & Nat Resources, Fac Engn & Technol, Dept Mech Biosyst Engn, Karaj, Alborz, Iran; Gyeongsang Natl Univ, Inst Smart Farm, Dept Biosyst Engn, Jinju, South Korea | ; Adesanya, Misbaudeen/AAA-4664-2022; Akpenpuun, Timothy/AAE-1168-2020; Narimani, Mohammadreza/MGU-9132-2025; Ogunlowo, Qazeem/GVR-8915-2022; RABIU, Anis/JXO-1947-2024 | whlee@knu.ac.kr; | JOURNAL OF AGRICULTURAL ENGINEERING | J AGRIC ENG-ITALY | 1974-7071 | 2239-6268 | 55 | 2 | SCIE | AGRICULTURAL ENGINEERING | 2024 | 2.5 | 37.5 | 1 | neural network; NARX; modeling; time series; algorithm | TEMPERATURE; PREDICTION | English | 2024 | 2024 | 10.4081/jae.2024.1563 | 바로가기 | 바로가기 | 바로가기 | |||||||||
| ○ | ○ | Article | Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era | Background Elderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) undergoing reduced intensity R-CHOP therapy are at a heightened risk of acquiring infections, notably coronavirus disease 2019 (COVID-19) infection. This study aimed to evaluate the efficacy of intravenous immunoglobulin (IVIG) as prophylaxis against COVID-19 in this vulnerable population.Methods A total of 125 elderly patients with DLBCL undergoing reduced intensity R-CHOP therapy were analyzed in this prospective, multicenter study. Patients with hypogammaglobulinemia were categorized into IVIG and non-IVIG groups, while those with normal immunoglobulin levels constituted the observation group. The study evaluated COVID-19 infection rates, therapy response, and safety outcomes.Results Among the enrolled patients (median age: 77 years), 89 patients (71.2%) presented with hypogammaglobulinemia at diagnosis, and 56 patients enrolled in the IVIG administration group. IVIG administration remarkably reduced COVID-19 infection rates compared to non-IVIG recipients (8.9% vs. 24.6%; p =0.040). Notably, patients over 80 years old were more susceptible to COVID-19. Patients on IVIG exhibited good tolerance with manageable adverse events. Among patients with hypogammaglobulinemia who received IVIG, 40.5% of patients developed additional immunoglobulin deficiencies during chemotherapy. One or more new hypogammaglobulinemia occurred during chemotherapy in 72% of patients with hypogammaglobulinemia who did not receive IVIG, and in 61.3% of patients who did not have hypogammaglobulinemia at diagnosis.Conclusion IVIG showed promise in reducing COVID-19 infections among elderly patients with DLBCL receiving reduced intensity R-CHOP therapy. This highlights IVIG's potential as a prophylactic measure, necessitating further investigation to optimize dosing, administration schedules, and potential interactions with vaccination strategies. | Baek, Dong Won; Song, Ga-Young; Lee, Ho Sup; Do, Young Rok; Lee, Ji Hyun; Yhim, Ho-Young; Moon, Joon Ho; Yang, Deok-Hwan | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, Daegu, South Korea; Chonnam Natl Univ, Dept Hematol, Hwasun Hosp, Gwangju, Chollanamdo, South Korea; Kosin Univ, Coll Med, Kosin Univ Gospel Hosp, Div Rheumatol,Dept Internal Med, Busan, South Korea; Keimyung Univ, Dongsan Med Ctr, Dept Hematol, Sch Med, Daegu, South Korea; Dong A Univ, Dept Internal Med, Div Hematol, Coll Med, Pusan, South Korea; Jeonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju, South Korea | 57191874272; 57193027251; 57218103550; 8960168300; 56813113800; 35785270600; 56568642700; 8701758000 | drydh1685@hotmail.com; | FRONTIERS IN ONCOLOGY | FRONT ONCOL | 2234-943X | 14 | SCIE | ONCOLOGY | 2024 | 3.3 | 37.6 | 0.52 | 2025-04-16 | 1 | 1 | COVID-19; diffuse large B-cell lymphoma; elderly; hypogammaglobulinemia; immunochemotherapy | CHRONIC LYMPHOCYTIC-LEUKEMIA; RITUXIMAB; CANCER | COVID-19; diffuse large B-cell lymphoma; elderly; hypogammaglobulinemia; immunochemotherapy | antibiotic agent; antifungal agent; antivirus agent; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; granulocyte colony stimulating factor; immunoglobulin; immunoglobulin A; immunoglobulin D; immunoglobulin G; immunoglobulin M; lactate dehydrogenase; pegylated granulocyte colony stimulating factor; unclassified drug; aged; Article; aspiration pneumonia; brain hemorrhage; cancer chemotherapy; cancer immunotherapy; cancer staging; chill; chronic hepatitis B; coronavirus disease 2019; diffuse large B cell lymphoma; drug efficacy; ECOG Performance Status; female; fever; human; immunoglobulin blood level; immunoglobulin deficiency; infection rate; intervention study; liver failure; major clinical study; male; multicenter study; multiple cycle treatment; nausea and vomiting; non ST segment elevation myocardial infarction; pandemic; Pneumocystis pneumonia; prospective study; reverse transcription polymerase chain reaction; thorax pain; treatment response; vaccination; very elderly; vulnerable population | English | 2024 | 2024-04-23 | 10.3389/fonc.2024.1380492 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Clinical Outcomes of Solid Organ Transplant Recipients Hospitalized with COVID-19: A Propensity Score-Matched Cohort Study | Background: Solid-organ transplant recipients (SOTRs) receiving immunosuppressive therapy are expected to have worse clinical outcomes from coronavirus disease 2019 (COVID-19). However, published studies have shown mixed results, depending on adjustment for important confounders such as age, variants, and vaccination status. Materials and Methods: We retrospectively collected the data on 7,327 patients hospitalized with COVID-19 from two tertiary hospitals with government-designated COVID-19 regional centers. We compared clinical outcomes between SOTRs and non-SOTRs by a propensity score-matched analysis (1:2) based on age, gender, and the date of COVID-19 diagnosis. We also performed a multivariate logistic regression analysis to adjust other important confounders such as vaccination status and the Charlson comorbidity index. Results: After matching, SOTRs (n=83) had a significantly higher risk of high-flow nasal cannula use, mechanical ventilation, acute kidney injury, and a composite of COVID-19 severity outcomes than non-SOTRs (n=160) (all P <0.05). The National Early Warning Score was significantly higher in SOTRs than in non-SOTRs from day 1 to 7 of hospitalization (P P for interaction=0.008 by generalized estimating equation). In multivariate logistic regression analysis, SOTRs (odds ratio [OR], 2.14; 95% confidence interval [CI], 1.12-4.11) and male gender (OR, 2.62; 95% CI, 1.26- 5.45) were associated with worse outcomes, and receiving two to three doses of COVID-19 vaccine (OR, 0.43; 95% CI, 0.24-0.79) was associated with better outcomes. Conclusion: Hospitalized SOTRs with COVID-19 had a worse prognosis than non-SOTRs. COVID-19 vaccination should be implemented appropriately to prevent severe COVID-19 progression in this population. | Lim, Jeong-Hoon; Nam, Eunkyung; Seo, Yu Jin; Jung, Hee-Yeon; Choi, Ji-Young; Cho, Jang-Hee; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim; Bae, Sohyun; Hwang, Soyoon; Kim, Yoonjung; Chang, Hyun-Ha; Kim, Shin-Woo; Jung, Juhwan; Kwon, Ki Tae | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Div Nephrol,Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Div Infect Dis,Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Dept Stat, Daegu, South Korea | Cho, Jang-hee/ABD-3534-2020; Kim, Jung/S-5543-2017; Lim, Jeong-Hoon/ABE-6003-2020; Hwang, Soyoon/HHM-5762-2022; Kim, Yong-Lim/AGK-3172-2022; Park, Sun-Hee/LMN-0033-2024; Jung, Hee-Yeon/AFB-8578-2022 | 55360244300; 58121908200; 59167627900; 57196396467; 7501393222; 7403536291; 7501831741; 8558530700; 55633533600; 57219699506; 59510718100; 59510682700; 7407521688; 57189703358; 59387017300; 9733850500 | ktkwon@knu.ac.kr; | INFECTION AND CHEMOTHERAPY | INFECT CHEMOTHER | 2093-2340 | 2092-6448 | 56 | 3 | ESCI | INFECTIOUS DISEASES | 2024 | 2.9 | 37.6 | 1.52 | 2025-05-07 | 2 | 2 | SARS-CoV-2; Immunization; Transplantation; Treatment outcome | MORTALITY | Immunization; SARS-CoV-2; Transplantation; Treatment outcome | corticosteroid; cyclosporine; dexamethasone; mycophenolic acid; regdanvimab; remdesivir; SARS-CoV-2 vaccine; tacrolimus; acute kidney failure; adult; aged; Article; artificial ventilation; Charlson Comorbidity Index; chronic kidney failure; clinical outcome; cohort analysis; comorbidity; congestive heart failure; coronavirus disease 2019; diabetes mellitus; disease course; disease severity; female; graft recipient; high flow nasal cannula therapy; hospital admission; hospitalization; human; major clinical study; male; middle aged; National Early Warning Score; organ transplantation; people by vaccination status; pneumonia; prognosis; retrospective study; sex difference; very elderly | English | 2024 | 2024-09 | 10.3947/ic.2024.0027 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | COVID-19 Vaccination Recommendations for 2024-2025 in Korea | The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024-2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations. | Park, Wan Beom; Hwang, Young Hoon; Kwon, Ki Tae; Noh, Ji Yun; Park, Sun Hee; Song, Joon Young; Choo, Eun Ju; Choi, Min Joo; Choi, Jun Yong; Heo, Jung Yeon; Choi, Won Suk; Comm Adult Immunization; Korean Soc Infect Dis | Seoul Natl Univ, Coll Med, Dept Internal Med, 101 Daehak Ro, Seoul 03080, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Internal Med Div Infect Dis, Daegu, South Korea; Korea Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea; Soonchunhyang Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis, Bucheon, South Korea; Catholic Kwandong Univ, Int St Marys Hosp, Coll Med, Div Infect Dis, Incheon, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea; Ajou Univ, Sch Med, Dept Infect Dis, Suwon, South Korea | Choi, Jun/AEH-4018-2022; Hwang, Soyoon/HHM-5762-2022; Choi, Won Suk/V-2730-2017; Park, Wan Beom/GLU-9886-2022 | 7402229219; 57366691800; 9733850500; 24587375200; 57208684295; 57214400146; 7003504447; 56727198200; 59657240700; 24587525000; 56718971800 | wbpark1@snu.ac.kr; | INFECTION AND CHEMOTHERAPY | INFECT CHEMOTHER | 2093-2340 | 2092-6448 | 56 | 4 | ESCI | INFECTIOUS DISEASES | 2024 | 2.9 | 37.6 | 0 | 2025-05-07 | 0 | 0 | Vaccination; COVID-19; SARS-CoV-2 | COVID-19; SARS-CoV-2; Vaccination | SARS-CoV-2 vaccine; adult; adverse drug reaction; aged; antimicrobial therapy; Article; clinical practice guideline; coronavirus disease 2019; female; health care personnel; high risk population; human; immunization; infection prevention; Korea; Korean (people); practice guideline; pregnant woman; Severe acute respiratory syndrome coronavirus 2; vaccination | English | 2024 | 2024-12 | 10.3947/ic.2024.0142 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study | Durvalumab consolidation is now the standard-of-care after concurrent chemoradiotherapy in patients with unresectable stage III non-small-cell lung cancer. Our multicenter retrospective study of 286 patients showed that elderly patients had similar survival outcomes but experienced more adverse events (AEs) than younger patients. Careful patient selection and AE monitoring are needed during durvalumab consolidation in elderly patients. Background: The PACIFIC trial demonstrated survival benefit of durvalumab after concurrent chemoradiotherapy (CCRT) in unresectable stage III non-small-cell lung cancer. Data on the effectiveness and safety of durvalumab in elderly patients is lacking. Methods: This retrospective study was conducted between September 2017 and September 2022. Progression-free survival (PFS), overall survival (OS), recurrence patterns, first subsequent treatment after recurrence, factors associated with survival outcomes, and adverse events (AEs) were compared. Results: Of the 286 patients, 120 (42.0%) were >= 70 years and 166 (58.0%) were = 50% was associated with improved PFS and OS. Elderly patients experienced more treatment-related AEs, grade 3/4 AEs, permanent discontinuation of durvalumab, and treatment-related deaths. Among the AEs leading to permanent discontinuation or death, pulmonary AE was significantly more common in elderly patients. Conclusion: Durvalumab demonstrated similar outcomes in elderly compared to younger patients. However, AEs were more common in elderly patients. Thus, judicious selection of patients and chemotherapy regimens, coupled with careful AE monitoring, are important factors for ensuring optimal durvalumab treatment. | Park, Ji Eun; Hong, Kyung Soo; Choi, Sun Ha; Lee, Shin Yup; Shin, Kyeong-Cheol; Jang, Jong Geol; Kwon, Yong Shik; Park, Sun Hyo; Choi, Keum-Ju; Jung, Chi Young; Eom, Jung Seop; Kim, Saerom; Seol, Hee Yun; Kim, Jehun; Kim, Insu; Park, Jin Han; Kim, Tae Hoon; Ahn, June Hong | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Yeungnam Univ, Coll Med, Dept Internal Med, Daegu, South Korea; Keimyung Univ, Sch Med, Dept Internal Med, Busan, South Korea; Daegu Catholic Univ, Coll Med, Dept Internal Med, Daegu, South Korea; Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea; Kosin Univ, Coll Med, Dept Internal Med, Busan, South Korea; Dong A Univ, Coll Med, Dept Internal Med, Busan, South Korea; Inje Univ, Coll Med, Dept Internal Med, Busan, South Korea; Gyeongsang Natl Univ, Sch Med, Dept Internal Med, Chang Won, South Korea; Yeungnam Univ, Coll Med, Dept Internal Med, Div Pulmonol & Allergy, 170 Hyeonchung Ro, Daegu 42415, South Korea; Yeungnam Univ, Resp Ctr, Med Ctr, 170 Hyeonchung Ro, Daegu 42415, South Korea | Kim, Chang-Hoon/D-7205-2016; Park, Sun Hyo/JVN-6216-2024; Ahn, June/AAB-3093-2019 | 57195437358; 56645558700; 57199723585; 49863712700; 35320479500; 56645456400; 57203804743; 57191525804; 58945401100; 57223991305; 57201262394; 57490278900; 57208402180; 57191899861; 57191965736; 57043777100; 56561312800; 56645445800 | fireajh@gmail.com; | CLINICAL LUNG CANCER | CLIN LUNG CANCER | 1525-7304 | 1938-0690 | 25 | 4 | SCIE | ONCOLOGY | 2024 | 3.3 | 37.6 | 3.66 | 2025-05-07 | 8 | 9 | Non-small cell lung cancer; Real-world data | CELL LUNG-CANCER; CONCURRENT CHEMORADIOTHERAPY | Non-small cell lung cancer; Real-world data | Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Consolidation Chemotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; cisplatin; durvalumab; steroid; durvalumab; immunological antineoplastic agent; monoclonal antibody; adult; aged; Article; cancer mortality; cancer recurrence; cancer staging; chemoradiotherapy; clinical effectiveness; clinical outcome; consolidation chemotherapy; controlled study; drug safety; drug withdrawal; ECOG Performance Status; fatigue; female; follow up; human; inoperable cancer; lung toxicity; major clinical study; male; myalgia; non small cell lung cancer; observational study; overall survival; progression free survival; radiation dose; radiation pneumonia; retrospective study; sex difference; side effect; very elderly; clinical trial; consolidation chemotherapy; drug therapy; lung tumor; middle aged; mortality; multicenter study; non small cell lung cancer; pathology; procedures; survival rate; therapy | English | 2024 | 2024-06 | 10.1016/j.cllc.2024.02.006 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Effectiveness and Tolerability of Dual Therapy with Dolutegravir Plus Darunavir/ cobicistat in Treatment-Experienced Patients with HIV: A 144-Week Follow-Up | Background: A dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG+DRV/c) is a promising alternative for patients with human immunodeficiency virus (HIV) with resistance or intolerance to nucleoside reverse transcriptase inhibitors, especially those with a history of treatment failure. Materials and Methods: We included all treatment-experienced patients with HIV who switched to the DTG+DRV/c regimen at a tertiary university hospital. We assessed the regimen's effectiveness, safety, and tolerability through serial laboratory data and clinical findings. The primary endpoint was the proportion of patients with plasma HIV-RNA levels <50 copies/mL at week 144 post-switch. The secondary endpoints were safety and tolerability assessments. Results: Our retrospective analysis involved 40 patients. The leading reasons for switching to DTG+DRV/c were treatment failure in 17 patients (42.5%), simplification after multiple previous regimens in 15 (37.5%), and adverse drug reactions in 8 (20.0%). Among the 17 patients in the treatment failure group, we observed enhanced viral suppression and improved CD4+ T-cell counts after initiating the dual regimen. In the non-treatment failure group (23 patients), viral suppression and CD4+ T-cell levels were consistently maintained. No significant alterations in renal function, liver function, glucose levels, or lipid profiles were observed post-switch. High tolerability was observed, with 34/40 patients (85.0%) responding well to the regimen. However, six patients discontinued treatment before reaching the 144-week mark. Conclusion: Our findings confirm that DTG+DRV/c is an effective and well-tolerated switch therapy regimen for treatment-experienced patients with HIV, with sustained benefits observed for up to 144 weeks of follow-up. This regimen showed adaptability across different patient groups and demonstrated virological and immunological improvements, particularly in patients with a history of treatment failure. | Kim, Shin-Woo; Jang, Hyun Wook; Chang, Hyun-Ha; Kim, Yoonjung; Bae, Sohyun | Kyungpook Natl Univ, Sch Med, Dept Internal Med, 130 Dongdeok Ro, Daegu 41944, South Korea | Kim, Jung/S-5543-2017; Kim, Ik-Sang/J-5425-2012 | 8710731500; 59222358100; 7407521688; 57203160508; 57219699506 | ksw2kms@knu.ac.kr; | INFECTION AND CHEMOTHERAPY | INFECT CHEMOTHER | 2093-2340 | 2092-6448 | 56 | 2 | ESCI | INFECTIOUS DISEASES | 2024 | 2.9 | 37.6 | 0 | 2025-05-07 | 1 | 1 | Human immunodeficiency virus; Treatment-experienced patients; Dolutegravir; Cobicistat-boosted darunavir; Antiretroviral therapy | BOOSTED DARUNAVIR; INFECTION; REGIMENS; SAFETY; SWITCH | Antiretroviral therapy; Cobicistat-boosted darunavir; Dolutegravir; Human immunodeficiency virus; Treatment-experienced patients | abacavir; atazanavir plus ritonavir; bictegravir; cobicistat; cobicistat plus darunavir; darunavir; didanosine; dolutegravir; emtricitabine; emtricitabine plus rilpivirine plus tenofovir disoproxil; glucose; lamivudine; lopinavir; raltegravir; rilpivirine; ritonavir; tenofovir alafenamide; tenofovir disoproxil; virus RNA; adult; antiretroviral therapy; Article; CD4+ T lymphocyte; controlled study; drug efficacy; drug safety; drug tolerability; drug withdrawal; female; follow up; glucose level; human; Human immunodeficiency virus infection; kidney function; lipid fingerprinting; liver function; major clinical study; male; medication compliance; middle aged; observational study; patient compliance; retrospective study; side effect | English | 2024 | 2024-06 | 10.3947/ic.2024.0006 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Epidemiological Characteristics of HIV-Infected Individuals by the Registration for Special Exempted Calculation: A Nationwide Cohort Study | Background: The Korean government is implementing policy to reduce medical costs and improve treatment related for human immunodeficiency virus (HIV) patients. The level of cost reduction and the benefits provided vary depending on how individuals with HIV utilize the system. This study aims to determine exact HIV prevalence by analyzing healthcare utilization patterns and examining differences in healthcare usage based on how individuals pay for their medical expenses. Materials and Methods: We analyzed National Health Insurance Service (NHIS) claims data from 2002 to 2021. From a total of 106,675 individuals with at least one HIV-related claim, 22,779 participants were selected for this study. Results: Data from Korea Disease Control and Prevention Agency annual reports indicated that 93% of HIV patients were male, while NHIS data showed 84%. In the analysis of those exempted from registration, it was found that the registration rate for female patients is notably low, with adults between the ages of 20 and 40 making up 80% of the total. The registration rate in Gangwon State was lower than Seoul. The treatment experience rate was much higher in the registered group (93.0%) than the unregistered group (4.9%). Also, there was a big difference in treatment continuity rates: 76.2% for registered individuals and 2.8% for non-registered individuals. Conclusion: The exempt calculation system for health insurance improves HIV care. However, those diagnosed anonymously or with reduced medical costs may be less likely to continue HIV treatment, so a new policy is needed to ensure anonymity and treatment continuity. | Choi, Yunsu; Ahn, Kyoung Hwan; Kim, Soo Min; Choi, Bo Youl; Choi, Jungsoon; Kim, Jung Ho; Kim, Shin-Woo; Kim, Youn Jeong; Jun, Yoon Hee; Park, Bo Young | Hanyang Univ, Inst Hlth & Soc, Seoul, South Korea; Hanyang Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Natl Food Safety Informat Serv, Off Policy Res, Seoul, South Korea; Hanyang Univ, Dept Math, Seoul, South Korea; Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Yonsei Univ, AIDS Res Inst, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Catholic Univ Korea, Incheon St Marys Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Incheon, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Div Infect Dis,Dept Internal Med, Seoul, South Korea; Univ Washington, Sch Med, Dept Urol, Seattle, WA USA; Fred Hutchinson Canc Ctr, Canc Prevent Program, Publ Hlth Sci, Seattle, WA USA | ; Kim, Jung Ho/LDE-9088-2024; Choi, Jungsoon/L-1944-2016 | 57195931031; 57832526400; 57194701617; 57236918400; 56050936700; 56657199800; 8710731500; 58528853000; 55187716200; 57217335056 | ychoi3@fredhutch.org; | INFECTION AND CHEMOTHERAPY | INFECT CHEMOTHER | 2093-2340 | 2092-6448 | 56 | 4 | ESCI | INFECTIOUS DISEASES | 2024 | 2.9 | 37.6 | 0 | 2025-05-07 | 1 | 1 | HIV care continuum; Antiretroviral therapy; HIV transmission; Medical service utilization; Exempted calculation system of health insurance | HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASES SOCIETY; POLICY PAPER; AMERICA; STIGMA; VISITS; KOREA; CARE | Antiretroviral therapy; Exempted calculation system of health insurance; HIV care continuum; HIV transmission; Medical service utilization | adult; aged; Article; cohort analysis; female; health care disparity; health care management; health care utilization; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus prevalence; major clinical study; male; national health insurance; patient registry; sex ratio | English | 2024 | 2024-12 | 10.3947/ic.2024.0085 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma | Background There is no established second-line treatment for hepatocellular carcinoma (HCC) following atezolizumab-bevacizumab (ate-beva) failure. This study assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) as a salvage therapy by comparing survival outcomes and treatment responses between HAIC as a first-line treatment and as a second-line option after ate-beva failure.Materials and Methods We retrospectively analyzed 100 patients with advanced HCC treated with HAIC between March 2022 and July 2024. Patients were categorized into two groups: those who received HAIC as initial therapy (first-line HAIC group) and those who received HAIC following ate-beva failure (post-ate-beva group). Survival outcomes were assessed with Kaplan-Meier curves and log-rank tests, and factors associated with survival were identified through Cox regression analysis.Results The post-ate-beva group exhibited longer overall survival (OS) (median OS 12.4 months) compared to the first-line HAIC group (median OS 6.8 months) (p = 0.073). Progression-free survival (PFS) was significantly superior in the post-ate-beva group (median PFS 8.2 months) compared to the first-line HAIC group (median PFS 3.1 months) (p = 0.018). The objective response rate was also notably higher in the post-ate-beva group than in the first-line HAIC group (35.3% vs. 18.1%, p = 0.031). In multivariate analysis, HAIC following ate-beva failure, compared to first-line HAIC, was significantly associated with favorable outcomes for both OS (p = 0.014) and PFS (p = 0.006).Conclusion The superior survival outcomes and treatment responses observed in the post-ate-beva group suggest that HAIC may be an effective second-line treatment option for advanced HCC following ate-beva therapy failure. However, due to the retrospective nature and small sample size of the study, further prospective studies with larger patient populations are needed to strengthen the evidence. | Lee, Ji Yeon; Lee, Jaejun; Kim, Suho; Yoo, Jae-sung; Kim, Ji Hoon; Yang, Keungmo; Han, Ji Won; Jang, Jeong Won; Choi, Jong Yong; Yoon, Seung Kew; Chun, Ho Jong; Oh, Jung Suk; Sung, Pil Soo | Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Div Hepatol,Dept Internal Med, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Radiol, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Catholic Univ Korea, Div Hepatol, Dept Internal Med, Uijeongbu St Marys Hosp, Seoul, South Korea | Jang, Jeong/LOS-2890-2024; Sung, Pil/K-2072-2019 | 55550492900; 56643301500; 57059585100; 58567192800; 58027048600; 57211494507; 57206611002; 7402965009; 57203732617; 59293877400; 15071454400; 57203592674; 57206341074 | oj-cumc@daum.net;pssung@catholic.ac.kr; | FRONTIERS IN ONCOLOGY | FRONT ONCOL | 2234-943X | 14 | SCIE | ONCOLOGY | 2024 | 3.3 | 37.6 | 0.47 | 2025-05-07 | 1 | 1 | carcinoma; hepatocellular; hepatic arterial infusion chemotherapy; atezolizumab; bevacizumab; immunogenic cell death; immunotherapy ` 2 | PLUS BEVACIZUMAB; SORAFENIB; LENVATINIB; TUMOR | atezolizumab; bevacizumab; carcinoma; hepatic arterial infusion chemotherapy; hepatocellular; immunogenic cell death; immunotherapy ` 2 | alanine aminotransferase; aspartate aminotransferase; atezolizumab; bevacizumab; bilirubin; cisplatin; fluorouracil; adult; aged; Article; cancer growth; cancer prognosis; cancer staging; chemoembolization; Child Pugh score; computer assisted tomography; continuous infusion; controlled study; Doppler flowmetry; drug efficacy; female; follow up; hepatic artery; Hepatitis C virus; human; intraarterial drug administration; liver cell carcinoma; major clinical study; male; middle aged; overall survival; progression free survival; prospective study; retrospective study; salvage therapy; second-line treatment; survival; tumor growth; tumor volume | English | 2024 | 2024-12-12 | 10.3389/fonc.2024.1495321 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Real-World Status in the Treatment of Latent Tuberculosis Infection in People Living with HIV in Korea | This retrospective study analyzed medical records of 1,392 people living with HIV (PLWH) diagnosed with latent tuberculosis infection (LTBI) at two provincial central hospitals from 2011 to 2022. LTBI was diagnosed in 152 patients (10.9%) patients aged >= 18 years. Among the 113 patients who initiated treatment, 96 (85.0%) completed isoniazid therapy, while 17 (15.0%) discontinued due to patient refusal, liver function test abnormalities, and other reasons. During a mean follow-up period of 55.0 +/- 31.0 months, two cases of active tuberculosis were reported in both the treatment non-completion group (3.6%) and the completion group (2.1%). This study provides recent real-world insights into LTBI treatment among PLWH in Korea. | Chang, Hyun-Ha; Nam, Hyun-Ju; Kim, Hyun Sook; Park, Kyung-Hwa; Bae, Sohyun; Kim, Yoonjung; Kim, Shin-Woo; Jung, Sook In | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Div Infect Dis, Daegu, South Korea; Chonnam Natl Univ, Med Sch, Dept Infect Dis, 42 Jebong Ro, Gwangju 61469, South Korea | ; JUNG, SOOK IN/AGO-2862-2022 | 7407521688; 57223996666; 59500228100; 57219637574; 57219699506; 57203160508; 8710731500; 7403676835 | sijung@chonnam.ac.kr; | INFECTION AND CHEMOTHERAPY | INFECT CHEMOTHER | 2093-2340 | 2092-6448 | 56 | 4 | ESCI | INFECTIOUS DISEASES | 2024 | 2.9 | 37.6 | 0 | 2025-05-07 | 0 | 0 | People living with HIV; Latent tuberculosis; Treatment; Outcomes | CARE; PERFORMANCE; QUALITY | Latent tuberculosis; Outcomes; People living with HIV; Treatment | isoniazid; adult; Article; CD4 lymphocyte count; central nervous system disease; chronic kidney failure; chronic liver disease; diabetes mellitus; female; follow up; health care organization; high risk population; human; human cell; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; Korea; latent tuberculosis; liver function test; lung tuberculosis; lymphadenitis; major clinical study; male; medical record; Mycobacterium tuberculosis; population; release assay; retrospective study; tuberculosis; United States | English | 2024 | 2024-12 | 10.3947/ic.2024.0126 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Recommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition | The Korean Society of Infectious Diseases has been regularly developing guidelines for adult immunization since 2007. In 2023, the guidelines for the following seven vaccines were revised: influenza, herpes zoster, pneumococcal, tetanus-diphtheria-pertussis (Tdap), human papillomavirus (HPV), meningococcal, and rabies vaccines. For the influenza vaccine, a recommendation for enhanced vaccines for the elderly was added. For the herpes zoster vaccine, a recommendation for the recombinant zoster vaccine was added. For the pneumococcal vaccine, the current status of the 15-valent pneumococcal conjugate vaccine and 20-valent PCV was described. For the Tdap vaccine, the possibility of using Tdap instead of tetanus -diphtheria vaccine was described. For the HPV vaccine, the expansion of the eligible age for vaccination was described. For the meningococcal vaccine, a recommendation for the meningococcal B vaccine was added. For the rabies vaccine, the number of pre -exposure prophylaxis doses was changed. This manuscript documents the summary and rationale of the revisions for the seven vaccines. For the vaccines not mentioned in this manuscript, the recommendations in the 3rd edition of the Vaccinations for Adults textbook shall remain in effect. | Choi, Won Suk; Song, Joon Young; Kwon, Ki Tae; Lee, Hyo-Jin; Choo, Eun Ju; Baek, Jihyeon; Chin, Bumsik; Kim, Woo Joo; Lee, Mi Suk; Park, Wan Beom; Han, Sang Hoon; Choi, Jun Yong; Yeom, Joon Sup; Lee, Jin-Soo; Choi, Hee-Jung; Choi, Young Hwa; Lee, Dong-Gun; Choi, Jung-Hyun; Cheong, Hee Jin | Korea Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Div Infect Dis,Chilgok Hosp, Daegu, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea; Soonchunhyang Univ, Bucheon Hosp, Dept Internal Med, Div Infect Dis, Bucheon, South Korea; Inha Univ, Sch Med, Dept Internal Med, Div Infect Dis, Incheon, South Korea; Natl Med Ctr, Dept Internal Med, Div Infect Dis, Seoul, South Korea; Kyung Hee Univ, Kyung Hee Univ Hosp, Sch Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Yonsei Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul, South Korea; Ewha Womans Univ, Sch Med, Dept Internal Med, Seoul, South Korea; Ajou Univ, Dept Internal Med, Coll Med, Suwon, South Korea | ; Lee, Dong-Gun/IWD-9833-2023; Kim, Woo Joo/D-2733-2015; Kim, Hanjin/KYP-2633-2024; Choi, Won/V-2730-2017; Park, Wan Beom/GLU-9886-2022; Choi, Jah/AAA-4835-2022; Kim, Hyunho/GQH-5608-2022; Yeom, Joon/Q-5559-2019; Kim, Woo/D-2733-2015; Choi, Won Suk/V-2730-2017 | 56718971800; 57214400146; 9733850500; 57371176600; 7003504447; 26644740900; 7102658932; 59207541300; 55759244100; 7402229219; 59855191800; 57791298700; 7004196941; 56162297100; 57217262202; 27167708700; 35316112300; 57224798349; 7102495865 | heejinmd@korea.ac.kr; | INFECTION AND CHEMOTHERAPY | INFECT CHEMOTHER | 2093-2340 | 2092-6448 | 56 | 2 | ESCI | INFECTIOUS DISEASES | 2024 | 2.9 | 37.6 | 3.04 | 2025-05-07 | 4 | 4 | Adult; Vaccination; Immunization; Guideline; Korea | ACELLULAR PERTUSSIS-VACCINE; PNEUMOCOCCAL CONJUGATE VACCINE; ANTIGEN-CONTENT DIPHTHERIA; ZOSTER SUBUNIT VACCINE; HERPES-ZOSTER; ADVISORY-COMMITTEE; INFLUENZA VACCINE; UPDATED RECOMMENDATIONS; UNITED-STATES; PHASE-III | Adult; Guideline; Immunization; Korea; Vaccination | diphtheria tetanus vaccine; Human papilloma virus vaccine; influenza vaccine; Meningococcus vaccine; Pneumococcus vaccine; rabies vaccine; vaccine; varicella zoster vaccine; adult; antimicrobial therapy; Article; communicable disease; genetic recombination; herpes zoster; human; immunization; influenza; medical society; nonhuman; pertussis; practice guideline; pre-exposure prophylaxis; publication; tetanus | English | 2024 | 2024-06 | 10.3947/ic.2023.0072 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy | This study explores hyperprogressive disease (HPD) in lung cancer patients receiving immune checkpoint inhibitors (ICIs), aiming to redefine HPD, identify risk factors, and assess its impact on survival. Utilizing three HPD definitions and incorporating new measurable lesions, the study found varying incidence rates and risk factors across definitions. Patients with HPD experienced significantly worse progression -free and overall survival, emphasizing the importance of accurately identifying at-risk patients during immunotherapy. Introduction: Immune checkpoint inhibitors (ICIs) may be associated with hyperprogressive disease (HPD). However, there is currently no standardized definition of HPD, with its risk factors and clinical implications remaining unclear. We investigated HPD in lung cancer patients undergoing immunotherapy, aiming to redefine HPD, identify risk factors, and assess its impact on survival. Methods: Clinical and radiologic data from 121 non-small cell lung cancer (NSCLC) patients with 136 immunotherapy cases were reviewed retrospectively. Three HPD definitions (Champiat et al., HPDc; Sa & acirc;da-Bouzid et al., HPDs; and Ferrara et al., HPDf) were employed. Additionally, all new measurable lesions on the post-treatment CT scan were incorporated in measuring the sum of longest diameters (SLD) to define modified HPD (mHPD). Results: Among the 121 patients, 4 (3.3%) had HPDc, 11 (9.1%) had HPDs, and none had HPDf. Adding all new measurable lesions increased HPD incidence by 5%-10% across definitions. Multivariate analysis revealed significantly lower progression-free survival (PFS) and overall survival (OS) for patients with HPDc (HR 5.25, P = .001; HR 3.75, P = .015) and HPDs (HR 3.74, P < .001; HR 3.46, P < .001) compared to those without. Patients with mHPD showed similarly poor survival outcomes as HPD patients. Liver metastasis at diagnosis was associated with HPDs, and a high tumor burden correlated with HPDc. Conclusions: The incidence and risk factors of HPD varied with different definitions, but mHPD identified more cases with poor outcomes. This comprehensive approach may enhance the identification of at-risk patients and lead to a better understanding of HPD in lung cancer during immunotherapy. | Djunadi, Trie Arni; Oh, Youjin; Lee, Jeeyeon; Yu, Jisang; Chung, Liam Il-Young; Lee, Yeunho; Kim, Leeseul; Hong, Timothy; Lee, Soowon; Shah, Zunairah; Park, Joo Hee; Yoon, Sung Mi; Chae, Young Kwang | Northwestern Univ, Feinberg Sch Med, Chicago, IL USA; Richmond Univ, Med Ctr, Dept Internal Med, Staten Isl, NY USA; John H Stroger Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL USA; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Univ Hawaii, Dept Pediat, Honolulu, HI USA; Ascension St Francis Hosp, Dept Internal Med, Evanston, IL USA; Northwestern Univ, Evanston, IL USA; Baylor Univ, Waco, TX USA; Roswell Pk Comprehens Care Ctr, Dept Hematol Oncol, Buffalo, NY USA; North Cent Bronx Hosp, Albert Einstein Coll Med, Jacobi Med Ctr, Dept Internal Med, Bronx, NY USA; Northwestern Univ, Feinberg Sch Med, Dept Internal Med Hematol & Oncol, 645 N Michigan Ave Suite 1006, Chicago, IL 60611 USA | ; Chung, Liam Il-Young/IQU-0821-2023 | 58019543600; 58461465600; 37079213100; 58560944700; 58018988700; 58536787300; 57219467939; 58892357400; 58891221400; 36817286700; 58019263900; 58019402300; 55664764400 | YCHAE@nm.org; | CLINICAL LUNG CANCER | CLIN LUNG CANCER | 1525-7304 | 1938-0690 | 25 | 4 | SCIE | ONCOLOGY | 2024 | 3.3 | 37.6 | 0.52 | 2025-05-07 | 1 | 1 | TO-LYMPHOCYTE RATIO; DISEASE; BLOCKADE; IMMUNE; OUTCOMES; THERAPY | Disease progression; Immunology; Prognosis; Respiratory tract tumors; Retrospective studies | Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Incidence; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; antineoplastic agent; ATM protein; AXL receptor tyrosine kinase; B Raf kinase; BRCA2 protein; BRG1 protein; cyclic AMP responsive element binding protein binding protein; cyclin dependent kinase inhibitor 1B; cyclin dependent kinase inhibitor 2B; discoidin domain receptor 2; DNA mismatch repair protein MSH2; epidermal growth factor receptor 2; F box/WD repeat containing protein 7; Fanconi anemia group A protein; Fanconi anemia group C protein; Fanconi anemia group D2 protein; immune checkpoint inhibitor; K ras protein; mammalian target of rapamycin; MutL protein homolog 1; myeloid differentiation factor 88; Notch1 receptor; Notch2 receptor; partner and localizer of BRCA2; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; protein kinase B beta; protein kinase LKB1; protein mcl 1; protein p53; Rad50 protein; scatter factor receptor; Smad4 protein; somatomedin C receptor; tuberin; xeroderma pigmentosum group D protein; immune checkpoint inhibitor; adult; aged; akt1 gene; arid1a gene; Article; axillary lymph node; bap gene; bone metastasis; brad1 gene; brain metastasis; cancer chemotherapy; cancer patient; cancer risk; cancer staging; cancer survival; ccne1 gene; checkpoint inhibitor therapy; cohort analysis; controlled study; copy number variation; disease exacerbation; ECOG Performance Status; fam123b gene; fanci gene; female; follow up; gnas gene; high throughput sequencing; human; human tissue; hyperprogressive disease; incidence; inoperable cancer; large cell lung carcinoma; left liver lobe; liver metastasis; lung adenocarcinoma; lung hilus; major clinical study; male; medical record review; mer11a gene; multivariate analysis; neutrophil lymphocyte ratio; nf1 gene; non small cell lung cancer; observational study; oncogene; overall survival; paraaortic lymph node; pik3r1 gene; platelet count; pole gene; progression free survival; rb1 gene; response evaluation criteria in solid tumors; retrospective study; right liver lobe; ros1 gene; single nucleotide polymorphism; slx4 gene; somatic mutation; squamous cell lung carcinoma; supraclavicular lymph node; treatment response; tumor mutational burden; tumor volume; x-ray computed tomography; disease exacerbation; drug therapy; immunotherapy; incidence; lung tumor; middle aged; non small cell lung cancer; pathology; procedures; prognosis; risk factor; survival rate; therapy; very elderly | English | 2024 | 2024-06 | 10.1016/j.cllc.2024.03.001 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: